Is Eli Lilly (LLY) a Buy Right Now?
A plain-English read on Eli Lilly stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Eli Lilly is currently trading at $1196.03, which is above its 200-day average of $1026.82. This suggests a long-term upward trend. The RSI, a gauge of whether a stock has climbed too far, too fast, sits at 58.5, indicating a balanced level of buying interest without being overextended.
The stock is currently positioned between its recent support floor of $1134.4 and its resistance ceiling of $1249.45. With a P/E ratio, or the price you pay for one dollar of company earnings, at 26.4, the valuation reflects the current market sentiment toward the firm's growth.
Should you buy Eli Lilly stock?
The data supports a buy position as the price maintains its momentum above key averages. However, always consider your own risk tolerance before entering a position. Market conditions can change, so keep an eye on the support level of $1134.4.
Is LLY a good stock for beginners?
Eli Lilly is a large, established company, which often brings more stability than smaller, speculative firms. While the stock has moved within a wide 52-week range of $623.78 to $1249.45, it remains a common choice for those learning how to track long-term trends.
What's driving LLY right now
The stock price is currently above its 200-day average of $1026.82, signaling a positive long-term direction.
The recent support level of $1134.4 provides a clear reference point for where the price has historically found buyers.
The stock is currently approaching its recent resistance level of $1249.45, which marks the top of its 52-week range.
An RSI of 58.5 shows the stock is neither overbought nor oversold, suggesting a healthy level of market activity.
What Eli Lilly actually does
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly by the numbers
Wall Street consensus on LLY is Buy. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Who owns Eli Lilly?
Institutions — pension funds, asset managers, index providers — hold 85.1% of LLY, and the concentration matters: the largest single holder alone controls 9.60% of the company.
| Holder | Shares | % held |
|---|---|---|
| 90.38M | 9.60% | |
| 66.38M | 7.05% | |
| 53.36M | 5.67% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Eli Lilly insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Eli Lilly, none were an open-market buy or sell — they are awards, vesting, option exercises or derivative conversions, which is normal and says nothing about conviction either way. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-20 | AWARD / VEST | 4 | $5.0K | |
| 2026-07-20 | AWARD / VEST | 10 | $12.4K | |
| 2026-07-20 | AWARD / VEST | 8 | $9.9K |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading LLY?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name LLY — filed by 11 separate members or more and worth $116K–$565K combined (filings report bands, never exact amounts). 12 purchase-side, 13 sale-side, most recently on 2026-07-10.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-07-10 | SELL | $1,001 - $15,000 | |
| 2026-06-10 | BUY | $50,001 - $100,000 | |
| 2026-04-14 | BUY | $1,001 - $15,000 |
Names withheld — plus 22 more records not shown.
See which membersWith the price holding above its 200-day average, the current data leans toward a buy for those comfortable with the stock's current momentum.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice LLY risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about LLY
Should I buy LLY stock?+
The data indicates a buy, as the price is currently trending upward above its 200-day average of $1026.82.
Is LLY a good long-term investment?+
The stock has shown significant growth over the past year, moving from a 52-week low of $623.78 to a high of $1249.45.
Is LLY a buy or a sell?+
Based on the current trend and the price of $1196.03 being above the 50-day average of $1146.36, the data supports a buy.
Is LLY overvalued?+
With a P/E ratio of 26.4 and an RSI of 58.5, the stock is currently trading in a balanced range relative to its recent history.
Is LLY a good stock for beginners?+
It is a large company with a clear trend, though beginners should note the 52-week range spans from $623.78 to $1249.45.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Eli Lilly (LLY) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-07-24 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.